Key result
Trial evaluates whether delayed remote ischemic preconditioning reduces 30-day MACCE in major vascular surgery.
Why the study?
There is a lack of Level I evidence regarding the efficacy and safety of delayed remote ischemic preconditioning in the perioperative period for vascular surgery patients.
Does delayed remote ischemic preconditioning (DRIPC) reduce major adverse cardiac and cerebrovascular events in patients undergoing major vascular surgery?
RCT (n=1,054)
Double-blind
Stratified block randomization
No
Does delayed remote ischemic preconditioning (DRIPC) reduce major adverse cardiac and cerebrovascular events in patients undergoing major vascular surgery?
This study protocol outlines a planned 1,054-patient randomized controlled trial to determine if delayed remote ischemic preconditioning reduces 30-day perioperative cardiovascular and cerebrovascular events in high-risk patients undergoing major vascular surgery.
Answers are grounded in this paper and cite their sources.
Leaves open whether delayed RIPC reduces 30-day MACCE in vascular surgery; this RCT will deliver definitive Level 1 evidence.
Introduction Although endovascular therapy has become the mainstream approach for major vascular surgery, patients undergoing such procedures are still classified as high-risk according to clinical guidelines. Remote ischemic preconditioning (RIPC) is a promising perioperative intervention strategy that has demonstrated acceptable safety and efficacy. Existing research indicates that delayed remote ischemic preconditioning (DRIPC) offers superior protective effects compared to preconditioning performed within 24 h before surgery. However, there is currently a lack of Level I evidence regarding the efficacy and safety of DRIPC in the perioperative period for vascular surgery patients. This study aims to provide high-level evidence on the effectiveness and safety of this intervention in a clinical setting. Methods and analysis The trial is a single-center, prospective, double-blind, randomized controlled clinical trial. A total of 1,054 patients will be recruited. The primary endpoints of the study include major adverse cardiac and cerebrovascular events (MACCE) within 30 days postoperatively. Ethics and dissemination This study has been approved by the Ethics Committee of West China Hospital of Sichuan University (approval number:2025-1846). The results will be submitted to a major clinical journal for peer review and publication. Clinical Trial registration identifier ChiCTR2600116987
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) conducted an RCT in Major vascular surgery (n=1,054). Delayed remote ischemic preconditioning (DRIPC) vs. Sham control (cuff inflated to an ineffective pressure of 50 mmHg) was evaluated on Composite incidence of major adverse cardiac and cerebrovascular events (MACCE) occurring within 30 days postoperatively. This study protocol outlines a randomized controlled trial to evaluate whether delayed remote ischemic preconditioning reduces the 30-day incidence of major adverse cardiac and cerebrovascular events in major vascular surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: